From the ASH abstract...I find this sentence most hopeful..."Six pts continue to receive weekly infusions of TTI-621; one pt with DLBCL and another with FL have experienced progression-free intervals of 161 and 70 days, respectively.". And also..."TTI-621 has been reasonably well tolerated. " The full abstract can be found at ...https://ash.confex.com/ash/2016/webprogram/Paper89978.html